Summit Therapeutics Inc.
SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials foā¦ read more
Healthcare
Biotechnology
11 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$19.38
Price+2.43%
$0.46
1Y
Price
Market Cap
$14.427b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-33.3%
3y CAGR-40.3%
5y CAGREarnings
-$1.080b
-387.8%
1y CAGR-334.8%
3y CAGR-248.3%
5y CAGREPS
-$1.44
-367.7%
1y CAGR-153.2%
3y CAGR-99.8%
5y CAGRBook Value
$658.860m
$751.182m
Assets$92.322m
Liabilities$15.504m
DebtDebt to Assets
2.1%
-
Debt to EBITDAFree Cash Flow
-$323.587m
-127.5%
1y CAGR-98.2%
3y CAGR-63.1%
5y CAGRNo items found.
Press Releases
Statements and updates from the company